Guardion Health Sciences (GHSI) 10-K 27 Feb 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Feb. 23, 2018	Jun. 30, 2017
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Registrant Name	Guardion Health Sciences, Inc.
Entity Central Index Key	1,642,375
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 0
Entity Common Stock, Shares Outstanding		40,329,475

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets
Cash	$ 4,735,230	$ 62,520
Accounts receivable	72,771	1,673
Inventories	154,730	43,999
Current portion of deposits and prepaid expenses	117,164	29,363
Total current assets	5,079,895	137,555
Deposits and prepaid expenses, less current portion	10,470	10,470
Property and equipment, net	95,597	114,020
Intangible assets, net of accumulated amortization of $53,659	620,741	0
Goodwill	1,563,520	0
Total assets	7,370,223	262,045
Current liabilities
Accounts payable and accrued liabilities	311,236	356,467
Accrued expenses and deferred lease costs	12,043	88,290
Line of credit	30,535	0
Due to related parties	146,133	91,483
Convertible notes payable	0	44,323
Promissory notes payable	0	10,251
Promissory notes payable related party	0	16,805
Total current liabilities	499,947	607,619
Commitments and contingencies
Stockholders’ Equity (Deficiency)
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 and 1,705,154 shares issued and outstanding at December 31, 2017 and December 31, 2016	0	1,705
Common stock, $0.001 par value; 90,000,000 shares authorized; 40,183,475 and 24,683,966 shares issued and outstanding at December 31, 2017 and December 31, 2016	40,183	24,684
Additional paid-in capital	33,696,049	20,278,244
Accumulated deficit	(26,865,956)	(20,650,207)
Total stockholders’ equity (deficiency)	6,870,276	(345,574)
Total liabilities and stockholders’ equity (deficiency)	$ 7,370,223	$ 262,045

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2017	Dec. 31, 2016
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	1,705,154
Preferred Stock, Shares Outstanding	0	1,705,154
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	90,000,000	90,000,000
Common Stock, Shares, Issued	40,183,475	24,683,966
Common Stock, Shares, Outstanding	40,183,475	24,683,966

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Revenue	$ 437,349	$ 141,029
Cost of goods sold	175,470	75,702
Gross profit	261,879	65,327
Operating expenses
Research and development	259,463	33,084
Sales and marketing	599,926	389,111
General and administrative	4,683,932	3,339,086
Loss on settlement of promissory notes and accounts payable	0	249,739
Total operating expenses	5,543,321	4,011,020
Loss from operations	(5,281,442)	(3,945,693)
Other expenses:
Interest expense and financing costs	23,727	1,104,557
Change in fair value of note	0	698,147
Total other expenses	23,727	1,802,704
Net loss	(5,305,169)	(5,748,397)
Adjustments related to Series A 8% convertible preferred stock:
Accretion of deemed dividend	(601,952)	(760,011)
Dividend declared	(308,628)	(35,018)
Net loss attributable to common shareholders	$ (6,215,749)	$ (6,543,426)
Net loss per common share - basic and diluted	$ (0.22)	$ (0.3)
Weighted average common shares outstanding - basic and diluted	27,868,353	21,800,719

Consolidated Statements of Stoc

Consolidated Statements of Stockholders’ Equity (Deficiency) - USD ($)	Total	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Beginning Balance at Dec. 31, 2015	$ (1,227,550)	$ 0	$ 0	$ 21,549	$ 12,857,682	$ (14,106,781)
Beginning Balance (in shares) at Dec. 31, 2015		0	0	21,548,924
Issuance of common stock for services	1,425,684	$ 0	$ 0	$ 740	1,424,944	0
Issuance of common stock for services (in shares)		0	0	740,000
Fair value of warrants issued for services	344,846	$ 0	$ 0	$ 0	344,846	0
Fair value of post-maturity warrants issued as additional interest on notes payable	575,673	0	0	0	575,673	0
Issuance of common stock - conversion of accrued management fees	602,741	$ 0	$ 0	$ 685	602,056	0
Issuance of common stock - conversion of accrued management fees (in shares)		0	0	684,933
Issuance of preferred stock	1,170,000	$ 1,170	$ 0	$ 0	1,168,830	0
Issuance of preferred stock (in shares)		1,170,000	0	0
Fair value of preferred stock - conversion of notes payable and related interest	784,888	$ 535	$ 0	$ 0	784,353	0
Fair value of preferred stock - conversion of notes payable and related interest (in shares)		535,154	0	0
Fair value of common stock - conversion of notes payable and related interest	1,385,516	$ 0	$ 0	$ 1,652	1,383,864	0
Fair value of common stock - conversion of notes payable and related interest (in shares)		0	0	1,651,732
Fair value of warrants issued with convertible notes payable	270,076	$ 0	$ 0	$ 0	270,076	0
Issuance of convertible notes payable - beneficial conversion feature	70,949	0	0	0	70,949	0
Accretion of beneficial conversion feature on preferred stock	0	0	0	0	760,011	(760,011)
Dividend on preferred stock	0	$ 0	$ 0	$ 58	34,960	(35,018)
Dividend on preferred stock (in shares)		0	0	58,377
Net loss	(5,748,397)	$ 0	$ 0	$ 0	0	(5,748,397)
Ending Balance at Dec. 31, 2016	(345,574)	$ 1,705	$ 0	$ 24,684	20,278,244	(20,650,207)
Ending Balance (in shares) at Dec. 31, 2016		1,705,154	0	24,683,966
Fair value of common stock issued for acquisition	2,287,500	$ 0	$ 0	$ 3,050	2,284,450	0
Fair value of common stock issued for acquisition (in shares)		0	0	3,050,000
Issuance of common stock for services	657,791	$ 0	$ 0	$ 649	657,142	0
Issuance of common stock for services (in shares)		0	0	649,300
Sale of common stock	5,000,001	$ 0	$ 0	$ 4,348	4,995,653	0
Sale of common stock (in shares)		0	0	4,347,827
Issuance of preferred stock	3,105,000	$ 0	$ 3,105	$ 0	3,101,895	0
Issuance of preferred stock (in shares)		0	3,105,000	0
Conversion of preferred stock	0	$ (1,705)	$ (3,105)	$ 6,982	(2,172)	0
Conversion of preferred stock (in shares)		(1,705,154)	(3,105,000)	6,981,938
Fair value of vested stock options	1,457,527	$ 0	$ 0	$ 0	1,457,527	0
Fair value of common stock - conversion of notes payable and related interest	13,200	$ 0	$ 0	$ 18	13,182	0
Fair value of common stock - conversion of notes payable and related interest (in shares)		0	0	18,082
Accretion of beneficial conversion feature on preferred stock	0	$ 0	$ 0	$ 0	601,952	(601,952)
Dividend on preferred stock	0	$ 0	$ 0	$ 452	308,176	(308,628)
Dividend on preferred stock (in shares)		0	0	452,362
Net loss	(5,305,169)	$ 0	$ 0	$ 0	0	(5,305,169)
Ending Balance at Dec. 31, 2017	$ 6,870,276	$ 0	$ 0	$ 40,183	$ 33,696,049	$ (26,865,956)
Ending Balance (in shares) at Dec. 31, 2017		0	0	40,183,475

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Operating Activities
Net loss	$ (5,305,169)	$ (5,748,397)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	118,821	60,129
Amortization of debt discount	0	431,681
Change in fair value of note	0	698,147
Accrued interest expense included in notes payable	(8,818)	86,711
Fair value of warrants issued as post-maturity interest	0	575,673
Stock-based compensation	1,932,268	787,684
Stock-based compensation - related parties	183,051	982,846
Management fee compensation expense	0	191,781
Loss on settlement of promissory notes payable and accounts payable	0	249,739
(Increase) decrease in -
Accounts receivable	(20,993)	(537)
Inventories	(17,439)	(13,436)
Deposits and prepaid expenses	(87,251)	14,587
Increase (decrease) in -
Accounts payable and accrued expenses	(121,919)	84,605
Accrued and deferred rent costs	(76,247)	(54,787)
Net cash used in operating activities	(3,403,696)	(1,653,574)
Investing Activities
Purchase of property and equipment	(37,280)	(3,354)
Cash assumed upon acquisition	4,895	0
Net cash used in investing activities	(32,385)	(3,354)
Financing Activities
Proceeds from issuance of convertible notes payable	0	136,000
Proceeds from issuance of promissory notes - related party	0	140,000
Proceeds from issuance of promissory notes	100,000	220,000
Payments on promissory notes	(149,000)	(151,000)
Proceeds from issuance of preferred stock	3,105,000	1,145,000
Proceeds from issuance of common stock	5,000,001	0
Line of credit	(1,860)	0
Increase in due to related parties	54,650	215,598
Net cash provided by financing activities	8,108,791	1,705,598
Cash:
Net increase	4,672,710	48,670
Balance at beginning of period	62,520	13,850
Balance at end of period	4,735,230	62,520
Supplemental disclosure of cash flow information:
Cash paid for - Interest	23,532	385
Cash paid for - Income taxes	0	0
Non-cash financing activities:
Issuance of common stock dividends on preferred stock	308,628	35,018
Issuance of common stock upon conversion of accrued management fees	0	410,960
Issuance of preferred stock upon conversion of notes payable and related interest	0	535,149
Issuance of common stock upon conversion of notes payable and related interest	13,562	687,369
Fair value of warrants issued in connection with promissory and convertible notes payable	0	270,075
Beneficial conversion feature associated with promissory and convertible notes payable	0	70,949
Fair value of common shares issued for acquisition allocated to:
Intangible assets	674,400	0
Goodwill	1,563,520	0
Other assets	$ 49,580	$ 0

Organization and Business Opera

Organization and Business Operations	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Organization and Business Operations Organization and Business Guardion Health Sciences, Inc. (the “Company”) was formed in December 2009 as a California limited liability company under the name P4L Health Sciences, LLC. On June 30, 2015, the Company converted from a California limited liability company to a Delaware corporation, changing its name from Guardion Health Sciences, LLC to Guardion Health Sciences, Inc. The Company is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z ® The Company recently acquired VectorVision, a company that specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and early treatment diabetic retinopathy study (“ETDRS”) visual acuity testing. VectorVision’s standardization system is designed to provide the practitioner or researcher with the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision develops, manufactures and sells equipment and supplies for standardized vision testing for use by eye doctors in clinical trials, for real-world vision evaluation, and industrial vision testing. The acquisition of VectorVision expands our technical portfolio and we believe it further establishes our position at the forefront of early detection, intervention and monitoring of a range of eye diseases. The Company has had limited commercial operations to date, and has primarily been engaged in research, development, commercialization, and capital raising. Going Concern and Liquidity The financial statements have been prepared assuming the Company will continue as a going concern. The Company has utilized cash in operating activities of $ 3,403,696 1,653,574 26,865,956 20,650,207 The Company’s auditors have also included explanatory language in their opinion that there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. The Company will continue to incur significant expenses for commercialization activities related to its lead product Lumega-Z, the MapcatSF medical device, and with respect to efforts to build the Company’s infrastructure. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of products other than Lumega-Z and the MapcatSF. The Company is continuing attempts to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Our financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of our financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in valuing assets acquired in business acquisitions, impairment testing of long term assets, accruals for potential liabilities, valuing equity instruments issued during the period, and realization of deferred tax assets. Actual results could differ from those estimates. The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as noted below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Level 2. Level 3. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The Company believes the carrying amount of its financial instruments (consisting of cash, accounts receivable, and accounts payable and accrued liabilities) approximates fair value due to the short-term nature of such instruments. The fair value of the Company’s line of credit, convertible notes payable and promissory notes approximates their carrying value given the interest rates of such notes. Cash balances are maintained at large, well-established financial institutions. At times, cash balances may exceed federally insured limits. Insurance coverage limits are $ 250,000 The Company evaluates the collectability of its trade accounts receivable based on multiple factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns is established through a provision reducing the carrying value of receivables. At December 31, 2017 and 2016, no allowance for doubtful accounts and returns was recorded. Inventories The Company’s inventories are stated at the lower of weighted-average cost or market. The cost of finished goods and raw materials is determined on a first-in, first-out basis. The Company evaluates its inventories for obsolescence and recoverability at each reporting period. Property and equipment are initially recorded at their historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to seven years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. In connection with our acquisition of VectorVision, Inc., we identified and allocated estimated fair values to intangible assets including goodwill and customer relationships. In accordance with Accounting Standard Codification (“ASC”) 350 – Intangibles – Goodwill and Other, we determined whether these assets are expected to have indefinite (such as goodwill) or limited useful lives, and for those with limited lives, we established an amortization period and method of amortization. Our goodwill and other intangible assets are subject to periodic impairment testing. We utilized the services of an independent third party valuation firm to assist us in identifying intangible assets and in estimating their fair values. The useful lives for our intangible assets other than goodwill were estimated based on Management’s consideration of various factors, including assumptions that market participants might use about sales expectations as well as potential effects of obsolescence, competition, technological progress and the regulatory environment. Because the future pattern in which the economic benefits of these intangible assets may not be reliably determined, amortization expense is generally calculated on a straight-line basis. The Company reviews long-lived assets, including property and equipment, identifiable intangible assets, and goodwill for impairment at each fiscal year end or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs. As of December 31, 2017 and 2016, the Company had not deemed any long-lived assets as impaired, and was not aware of the existence of any indicators of impairment at such dates. The Company’s revenue is comprised of sales of medical foods and dietary supplements to consumers through a direct sales/credit card process. In addition, the Company sells medical device equipment and supplies to consumers both in the U.S. and internationally. Revenue is recognized when the risk of loss transfers to our customers, and collection of the receivable is reasonably assured, which generally occurs when the product is shipped. A product is not shipped without an order from the customer and credit acceptance procedures performed. The Company allows for returns within 30 days of purchase. Product returns for the years ended December 31, 2017 and 2016 were insignificant. Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures, which include patent related costs and stock compensation expense, are expensed as incurred and totaled $ 259,463 33,084 The Company is the owner of one issued domestic patent, three pending domestic patent applications, and three foreign patent applications in Canada, Europe and Hong Kong. Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, patent costs, including patent-related legal fees, filing fees and internally generated costs, are expensed as incurred. During the years ended December 31, 2017 and 2016, patent costs were $ 30,789 30,942 When conventional convertible debt is issued with detachable warrants, the proceeds from issuance are allocated to the two instruments based on their relative fair values. This method is generally appropriate if debt is issued with any other freestanding instrument that is classified in equity. When the convertible debt instrument includes both detachable instruments such as warrants, and a beneficial conversion option, the proceeds of issuance are allocated among the convertible instrument and the other detachable instruments based on their relative fair values as indicated above, and the amount allocated to the convertible instrument is further analyzed to determine if the embedded conversion option has intrinsic value. If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value, then the conversion option has intrinsic value and this feature is characterized as a beneficial conversion feature (“BCF”). The Company calculates an effective conversion price based on the fair value allocated to the convertible instrument divided by the number of conversion shares based upon the conversion terms of the instrument. The resulting calculation or effective conversion price is used to measure the intrinsic value, if any, of the embedded conversion option. Stated differently, intrinsic value is calculated at the commitment date as the difference between the conversion price (effective or otherwise) and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. If the intrinsic value of the BCF is greater than the proceeds allocated to the convertible instrument, the amount of the discount assigned to the BCF is limited to the amount of the proceeds allocated to the convertible instrument. A BCF is recorded by the Company as a debt discount and in those circumstances, the convertible debt will be recorded net of the discount related to the BCF. The Company amortizes the discount to interest expense over the life of the debt using the effective interest rate method or the straight-line method, as an approximation of effective interest amortization. The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers and directors, and to employees which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations based on a graded vesting schedule over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period using a graded vesting basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading market for its common stock, estimated volatility is based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date; the Company has never declared or paid dividends on its common stock and has no plans to do so for the foreseeable future. The fair value common stock was determined based on management’s judgment. In order to assist management in calculating such fair value, we retained a third-party valuation firm in determining the value of our Company. The third-party valuation firm’s input was utilized in determining the related per unit or share valuations of our equity used during 2017 and 2016. Management used valuations of $ 1.00 0.88 0.88 1.00 Year Ended December 31, 2017 2016 Discount rate 16 % 16 % Risk-free rate 2.48 % 2.27 % Rate of return 16 % 16 % Sustainable growth rate 5 % 5 % Company survival probability 65 % 63 % Liquidation value $ 0 $ 0 Due to the availability of historical data from the Company’s recent preferred and common stock sales, Management used a valuation of $ 0.75 1.15 1.15 0.88 The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises. During the years ended December 31, 2017 and 2016, we recognized aggregate stock-compensation expense of $ 2,115,346 1,962,311 0.88 1.25 2,094,360 1,811,990 20,357 145,214 628 5,107 The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing a variety of products that support the detection, intervention and monitoring of a range of eye diseases. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. The Company currently accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company determines that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2017 and 2016 and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of December 31, 2017, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense. On December 22, 2017, the President of the United States signed and enacted into law H.R. 1 (the “Tax Reform Law”). The Tax Reform Law, effective for tax years beginning on or after January 1, 2018, except for certain provisions, resulted in significant changes to existing United States tax law, including various provisions that will impact the Company. The Tax Reform Law reduces the federal corporate tax rate from 35 21 The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants, options, and shares associated with convertible debt outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares issuable upon exercise of warrants and conversion of convertible debt outstanding are anti-dilutive as they decrease loss per share. December 31, 2017 2016 Warrants 2,983,666 2,923,666 Options 950,000 - Shares issuable upon conversion of convertible preferred stock - 2,841,930 3,933,666 5,765,596 In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Based on the FASB’s Exposure Draft Update issued on April 29, 2015, and approved in July 2015, Revenue from Contracts With Customers (Topic 606): Deferral of the Effective Date, ASU 2014-09 is now effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company has not yet evaluated the impact of the adoption of ASU 2016-02 on the Company’s financial statement presentation or disclosures. In March 2016, the FASB issued Accounting Standards Update No. 2016-09 (ASU 2016-09), Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 requires, among other things, that all income tax effects of awards be recognized in the statement of operations when the awards vest or are settled. ASU 2016-09 also allows for an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and allows for a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for any entity in any interim or annual period. The adoption of ASU 2016-09 has not had any impact on the Company’s financial statement presentation or disclosures. Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	3. Inventories December 31, 2017 2016 Raw materials $ 133,354 $ 40,679 Finished goods 21,376 3,320 $ 154,730 $ 43,999

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	4. Property and Equipment, net December 31, 2017 2016 Leasehold improvements $ 98,357 $ 98,357 Testing equipment 150,603 145,503 Furniture and fixtures 50,300 15,348 Computer equipment 16,464 15,277 Office equipment 8,193 2,694 323,917 277,179 Less accumulated depreciation and amortization (228,320) (163,159) $ 95,597 $ 114,020 For the years ended December 31, 2017 and 2016, depreciation and amortization expense was $ 65,161 60,129 29,574 27,490 35,587 32,639

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2017
Convertible Notes Payable [Member]
Debt Disclosure [Text Block]	5. Convertible Notes Payable December 31, 2017 2016 Year of issuance: 2010 $ - $ 25,000 Accrued interest - 19,323 Convertible notes payable $ - $ 44,323 2016 and Prior Issuances In July 2010, the Company issued an unsecured convertible note payable in the amount of $ 25,000 12 0.08 19,323 In May 2015, the Company issued a convertible note in the principal amount of $ 500,000 5 500,000 41,644 1,408,854 1,239,792 0.88 698,147

Promissory Notes

Promissory Notes	12 Months Ended
	Dec. 31, 2017
Promissory Notes Payable [Member]
Debt Disclosure [Text Block]	6. Promissory Notes December 31, 2017 2016 Year of issuance: 2016 $ - $ 10,000 Accrued interest - 251 Promissory notes payable, net $ - $ 10,251 In 2016, the Company issued $ 170,000 4 9 10,000 449 100,000 120 6 0.75 8,000 18,082 13,200

Promissory Notes - Related Part

Promissory Notes - Related Party	12 Months Ended
	Dec. 31, 2017
Investor [Member]
Debt Disclosure [Text Block]	7. Promissory Notes – Related Party December 31, 2017 2016 Year of issuance: 2016 $ - $ 14,000 Accrued interest - 2,805 Promissory notes payable – related party, net $ - $ 16,805 In 2016, the Company issued $ 140,000 6 12 14,000

Acquisition of VectorVision

Acquisition of VectorVision	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	8. Acquisition of VectorVision On September 29, 2017, the Company, through a wholly-owned subsidiary, completed the acquisition of substantially all of the assets and liabilities of VectorVision, Inc., an Ohio corporation (“VectorVision”), in exchange for 3,050,000 2,287,500 With respect to the 3,050,000 shares of common stock, 250,000 shares were held back as security for VectorVision’s indemnification obligations to the Company and the remaining 2,800,000 shares were issued to VectorVision at the closing of the transaction. 11 VectorVision develops, manufactures and sells equipment and supplies for standardized vision testing for use by eye doctors in clinical trials, for real-world vision evaluation, and industrial vision testing. VectorVision specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity testing. VectorVision developed and commercialized its CSV-1000 medical device to conduct contrast sensitivity testing and it developed and commercialized its ESV-3000 medical device to conduct ETDRS visual acuity testing. The patented standardization system provides the practitioner or researcher with the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. The Company believes VectorVision’s CSV-1000 device to be the standard of care for clinical trials. The acquisition of VectorVision expands the Company’s technical portfolio and the Company believes it further establishes the Company’s position at the forefront of early detection, intervention and monitoring of a range of eye diseases. The Company accounted for the acquisition pursuant to Accounting Standards Codification Topic 805, Business Combinations (“ASC 805”). Management identified and evaluated the preliminary fair values of the assets acquired, relying in part, on the work of an independent third party valuation firm engaged by the Company to provide input as to the fair value of the consideration paid (because there is no established trading market for the Company’s Common Stock) and the assets acquired, including the valuation methodology most relevant to the transactions described herein, and to assist in the related calculations, analysis and allocations. Historical transactions, as well as the income, market and cost approaches to value were considered. Management ultimately determined that due to recent sales of the Company’s preferred stock and consideration of current business and market factors, that the use of historical transactions, and a value of $ 0.75 In accordance with ASC 805, the Company utilized the acquisition method of accounting, whereby the purchase consideration is allocated to specific tangible and intangible assets at their estimated fair values on the date of acquisition. Fair Values Common stock consideration $ 2,287,500 Liabilities assumed 108,722 Total purchase consideration 2,396,222 Cash (4,895) Accounts receivable (50,105) Inventory (93,293) Prepaid assets (551) Property and equipment (9,458) Intangible assets (674,400) Goodwill $ 1,563,520 Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the expected revenue and benefits of the combined company. The Company has consolidated VectorVision’s operations with the Company’s statement of operations commencing October 1, 2017. Year ended 2017 2016 Pro forma net revenues $ 824,028 $ 372,487 Pro forma net loss attributable to common shareholders $ (6,500,590) $ (6,910,705) Pro forma net loss per share $ (0.21) $ (0.28)

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	9. Commitments and Contingencies Operating Lease In October 2012, the Company entered into a lease agreement for 9,605 10,387 47,449 36,979 10,470 In connection with the acquisition of VectorVision on September 29, 2017, the Company assumed a lease agreement for 5,000 1,799 As of December 31, 2017 and 2016, the Company had accrued and deferred rent payable for its office and warehouse facilities under its lease agreement in the aggregate of $ 1,650 88,290 Years ending December 31, 2018 $ 93,000 2019 20,898 2020 21,520 2021 22,174 2022 and thereafter 26,670 $ 184,262 Rent expense was $ 111,167 106,217 Contingencies The Company is periodically the subject of various pending or threatened legal actions and claims arising out of its operations in the normal course of business. In the opinion of management of the Company, adequate provision has been made in the Company’s condensed financial statements at December 31, 2017 with respect to such matters, including the matter noted below. On or about July 26, 2017, the Company received a payment demand from a former consultant to the Company alleging that the consultant is owed approximately $ 192,000

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit)	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	10. Stockholders’ Equity (Deficit) Preferred Stock Series A During 2016, the Company sold 1,170,000 1.00 1,170,000 535,154 784,888 535,149 1.00 8 0.60 At the option of each holder, the Series A Preferred Stock (including accrued but unpaid dividends) may be converted into shares of the Company’s common stock commencing January 1, 2017 at $0.60 per share. The Series A Preferred Stock (including accrued but unpaid dividends) shall automatically convert into shares of common stock in the event that the Company receives gross proceeds of at least $4,000,000 in one or more equity financing transactions subsequent to September 30, 2016, or if the ten (10) day Volume Weighted Average Price per share of common stock is $2.00 or more. The issuance of the 1,170,000 shares of Series A Preferred Stock gave rise to a beneficial conversion feature due to the stated conversion price of $0.60 per share being less than the market price of the shares of Series A Preferred Stock at the issuance date as determined by an independent third-party valuation firm. The Company accounted for the beneficial conversion features in accordance with ASC 470-20, Accounting for Debt with Conversion and Other Options. The Company calculated a total deemed dividend on the Series A Preferred Stock of $ 779,586 760,011 19,575 During the year ended December 31, 2017, the Company declared dividends of $ 114,736 191,227 Series B Beginning in March 2017 and through September 30, 2017, the Company sold 3,105,000 1.00 3,105,000 6 0.75 Certain purchasers of 300,000 60,000 The stock is automatically convertible by the Company upon an equity financing of at least $5,000,000 subsequent to June 30, 2017, or in the event the Company’s common stock is publicly traded for at least $2.00 per share for 10 consecutive trading days, or upon completion of a Major Transaction (as defined in the Certificate of Designation). The issuance of the Series B Preferred Stock gave rise to a beneficial conversion feature due to the stated conversion price of $0.75 per share being less than the market price of the shares at the issuance date. In addition, 60,000 582,377 414,293 During the year ended December 31, 2017, the Company declared dividends of $ 193,892 261,135 Both classes of preferred stock will vote with the common stock on an “as converted” basis and have standard anti-dilution rights, exclusive of price protection. Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, no distribution shall be made to the holders of any shares of common stock of the Company unless, prior thereto, the holders of all classes of preferred stock shall have received out of the available assets of the Company, whether capital or surplus, an amount equal to 100% of the stated value, plus any accrued and unpaid dividends thereon. If the assets of the Company are insufficient to pay in full such amounts due the holders of the preferred stock, then the entire assets shall be distributed ratably among the holders of the preferred stock, first to holders of Series A Preferred Stock, then to holders of Series B Preferred Stock, in accordance with the respective preferences and amounts that would be payable on such shares of preferred stock if all amounts payable thereon were paid in full. Preferred shareholders of both series have unlimited piggyback registration rights. Holders of a majority of the shares of preferred stock (based on the $1.00 stated value) outstanding shall have the right to one demand registration during the three (3) years following the effective date of the Company’s registration statement under the Securities Exchange Act of 1934, so long as at least $ 500,000 250,000 Preferred Stock Conversion Event On November 3, 2017, the Company completed the issuance and sale of an aggregate of 4,347,827 6,981,938 205,242 Common Stock Sale of shares On November 3, 2017, the Company completed the issuance and sale of an aggregate of 4,347,827 shares of common stock, par value $ 0.001 1.15 5,000,001 Shares issued with vesting requirements The Company periodically issues shares of common stock to service providers that vest over time. As of December 31, 2015, there were 1,007,500 833,680 During 2016, the Company issued an additional 145,000 145,438 1.00 864,752 113,754 During 2017, the Company issued an additional 162,500 143,000 0.88 Number Fair Value Weighted Average Non-vested, December 31, 2015 1,007,500 $ 833,068 $ 1.14 Issued 145,000 145,438 1.00 Vested (800,000) (864,752) 1.12 Forfeited - - - Non-vested, December 31, 2016 352,500 113,754 1.13 Issued 162,500 143,000 0.88 Vested (515,000) (256,754) 1.05 Forfeited - - - Non-vested, December 31, 2017 - $ - $ - Other issuances During 2016, the Company also issued 595,000 560,932 During 2017, the Company also issued 486,800 401,037 On December 31, 2016, the Company issued 684,933 602,741 410,960 191,781 During 2016, the Company issued 1,651,732 1,385,516 687,368 698,147 Share adjustment In 2015, the Company issued 1,053,227 690,755 1,053,227 362,472 Warrants During 2016, in connection with a related party investor’s short-term loan agreements with maturity dates ranging from December 29, 2015 to April 24, 2016, the Company agreed to issue interest in the form of warrants (the “post-maturity warrants”) in addition to the continued accrual of the stated interest ( 12 0.25 585,000 575,673 1.00 118 1.01 575,673 In May 2016, the Company issued warrants to purchase 250,000 0.25 246,341 1.00 116 1.08 246,341 In June 2016, the Company issued warrants to purchase 100,000 0.25 98,505 1.00 116 1.07 98,505 Shares December 31, 2015 1,335,166 Granted 1,588,500 Forfeitures - Exercised - December 31, 2016 2,923,666 Granted 60,000 Forfeitures - Exercised - December 31, 2017, all exercisable 2,983,666 As of December 31, 2017, the Company had an aggregate of 2,983,666 0.37 0.9 1,293,512 0.88 Stock Options On September 30, 2017, the Company entered into a consulting agreement pursuant to which the Company issued a total of 1,250,000 650,000 1.00 5 years 934,804 0.75 123 1.63 878,818 On November 10, 2017, the Company issued 125,000 1.15 10 years 143,750 1.15 123 2.01 143,750 On December 30, 2017, the Company entered into a consulting agreement pursuant to which the Company issued a total of 750,000 250,000 1.25 5 years 936,834 1.25 123 2.01 434,959

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	11. Related Party Transactions On September 29, 2017, we completed the acquisition of substantially all of the assets and liabilities of VectorVision Ohio in exchange for 3,050,000 28 72 3 entitled to compensation of $10,000 per month for the first six months of the term of the Consulting Agreement and $7,500 per month for the remainder of the term of the Consulting Agreement. Due to and from related parties represents unreimbursed expenses and compensation incurred on behalf of, and amounts loaned to the Company by, Michael Favish, the Company’s Chief Executive Officer, as well as other shareholders. The advances are unsecured, non-interest bearing and are due on demand. As of December 31, 2017 and 2016, the Company had $ 146,133 91,483 During the twelve months ended December 31, 2017, the Company incurred $ 250,000 170,000 250,000 48,500 On December 31, 2016, the Company issued 684,933 602,741 410,960 191,781 On December 31, 2016, the Company awarded stock grants to its management and directors as compensation for services rendered. This included 50,000 20,000 15,000 5,000 162,800

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	12. Income Taxes December 31, 2017 2016 Net operating loss carryforwards $ 1,551,000 $ 3,356,000 Stock-based compensation 504,000 2,016,000 Deferred rent - 9,000 Accrued compensation 17,000 - Depreciation 5,000 1,000 Total deferred tax assets 2,077,000 5,382,000 Valuation allowance (2,077,000) (5,382,000) Net deferred tax assets $ - $ - In assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2017, management was unable to determine if it is more likely than not that the Company’s deferred tax assets will be realized and has therefore recorded an appropriate valuation allowance against deferred tax assets at such dates. No federal tax provision has been provided for the years ended December 31, 2017 and 2016, due to the losses incurred during the periods. Year Ended December 31, 2017 2016 U. S. federal statutory tax rate (35.0) % (35.0) % Share-based compensation 4.3 % 0.0 % State taxes, net of Federal benefit 0.0 % (6.0) % Adjustment to beginning deferred tax asset 68.5 % 0.0 % Change in valuation allowance (38.0) % 41.0 % Other 0.2 % 0.0 % Effective tax rate 0.0 % 0.0 % At December 31, 2017, the Company has available net operating loss carryforwards for federal income tax purposes of approximately $ 5,566,000 2035

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	13. Subsequent Events On January 25, 2018, the Company entered into an agreement with a consultant to develop products based on certain intellectual property owned by the Company. In conjunction with the consulting agreement, the Company issued a stock option on January 26, 2018 to the consultant to purchase a total of 500,000 5 years 1.25 250,000 125,000 125,000

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Use Of Estimates Policy [Policy Text Block]	Use of Estimates Our financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of our financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Significant estimates include those related to assumptions used in valuing assets acquired in business acquisitions, impairment testing of long term assets, accruals for potential liabilities, valuing equity instruments issued during the period, and realization of deferred tax assets. Actual results could differ from those estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as noted below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Level 2. Level 3. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The Company believes the carrying amount of its financial instruments (consisting of cash, accounts receivable, and accounts payable and accrued liabilities) approximates fair value due to the short-term nature of such instruments. The fair value of the Company’s line of credit, convertible notes payable and promissory notes approximates their carrying value given the interest rates of such notes.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties Cash balances are maintained at large, well-established financial institutions. At times, cash balances may exceed federally insured limits. Insurance coverage limits are $ 250,000
Accounts Receivable, Policy [Policy Text Block]	Accounts Receivable The Company evaluates the collectability of its trade accounts receivable based on multiple factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns is established through a provision reducing the carrying value of receivables. At December 31, 2017 and 2016, no allowance for doubtful accounts and returns was recorded.
Inventory, Policy [Policy Text Block]	Inventories The Company’s inventories are stated at the lower of weighted-average cost or market. The cost of finished goods and raw materials is determined on a first-in, first-out basis. The Company evaluates its inventories for obsolescence and recoverability at each reporting period.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are initially recorded at their historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from three to seven years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets In connection with our acquisition of VectorVision, Inc., we identified and allocated estimated fair values to intangible assets including goodwill and customer relationships. In accordance with Accounting Standard Codification (“ASC”) 350 – Intangibles – Goodwill and Other, we determined whether these assets are expected to have indefinite (such as goodwill) or limited useful lives, and for those with limited lives, we established an amortization period and method of amortization. Our goodwill and other intangible assets are subject to periodic impairment testing. We utilized the services of an independent third party valuation firm to assist us in identifying intangible assets and in estimating their fair values. The useful lives for our intangible assets other than goodwill were estimated based on Management’s consideration of various factors, including assumptions that market participants might use about sales expectations as well as potential effects of obsolescence, competition, technological progress and the regulatory environment. Because the future pattern in which the economic benefits of these intangible assets may not be reliably determined, amortization expense is generally calculated on a straight-line basis.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets The Company reviews long-lived assets, including property and equipment, identifiable intangible assets, and goodwill for impairment at each fiscal year end or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs. As of December 31, 2017 and 2016, the Company had not deemed any long-lived assets as impaired, and was not aware of the existence of any indicators of impairment at such dates.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company’s revenue is comprised of sales of medical foods and dietary supplements to consumers through a direct sales/credit card process. In addition, the Company sells medical device equipment and supplies to consumers both in the U.S. and internationally. Revenue is recognized when the risk of loss transfers to our customers, and collection of the receivable is reasonably assured, which generally occurs when the product is shipped. A product is not shipped without an order from the customer and credit acceptance procedures performed. The Company allows for returns within 30 days of purchase. Product returns for the years ended December 31, 2017 and 2016 were insignificant.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures, which include patent related costs and stock compensation expense, are expensed as incurred and totaled $ 259,463 33,084
Patent Costs Policy [Policy Text Block]	Patent Costs The Company is the owner of one issued domestic patent, three pending domestic patent applications, and three foreign patent applications in Canada, Europe and Hong Kong. Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, patent costs, including patent-related legal fees, filing fees and internally generated costs, are expensed as incurred. During the years ended December 31, 2017 and 2016, patent costs were $ 30,789 30,942
Debt, Policy [Policy Text Block]	Convertible Notes Payable When conventional convertible debt is issued with detachable warrants, the proceeds from issuance are allocated to the two instruments based on their relative fair values. This method is generally appropriate if debt is issued with any other freestanding instrument that is classified in equity. When the convertible debt instrument includes both detachable instruments such as warrants, and a beneficial conversion option, the proceeds of issuance are allocated among the convertible instrument and the other detachable instruments based on their relative fair values as indicated above, and the amount allocated to the convertible instrument is further analyzed to determine if the embedded conversion option has intrinsic value. If the conversion features of conventional convertible debt provide for a rate of conversion that is below market value, then the conversion option has intrinsic value and this feature is characterized as a beneficial conversion feature (“BCF”). The Company calculates an effective conversion price based on the fair value allocated to the convertible instrument divided by the number of conversion shares based upon the conversion terms of the instrument. The resulting calculation or effective conversion price is used to measure the intrinsic value, if any, of the embedded conversion option. Stated differently, intrinsic value is calculated at the commitment date as the difference between the conversion price (effective or otherwise) and the fair value of the common stock or other securities into which the security is convertible, multiplied by the number of shares into which the security is convertible. If the intrinsic value of the BCF is greater than the proceeds allocated to the convertible instrument, the amount of the discount assigned to the BCF is limited to the amount of the proceeds allocated to the convertible instrument. A BCF is recorded by the Company as a debt discount and in those circumstances, the convertible debt will be recorded net of the discount related to the BCF. The Company amortizes the discount to interest expense over the life of the debt using the effective interest rate method or the straight-line method, as an approximation of effective interest amortization.
Compensation Related Costs, Policy [Policy Text Block]	Stock-Based Compensation The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers and directors, and to employees which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations based on a graded vesting schedule over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award. The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period using a graded vesting basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading market for its common stock, estimated volatility is based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date; the Company has never declared or paid dividends on its common stock and has no plans to do so for the foreseeable future. The fair value common stock was determined based on management’s judgment. In order to assist management in calculating such fair value, we retained a third-party valuation firm in determining the value of our Company. The third-party valuation firm’s input was utilized in determining the related per unit or share valuations of our equity used during 2017 and 2016. Management used valuations of $ 1.00 0.88 0.88 1.00 Year Ended December 31, 2017 2016 Discount rate 16 % 16 % Risk-free rate 2.48 % 2.27 % Rate of return 16 % 16 % Sustainable growth rate 5 % 5 % Company survival probability 65 % 63 % Liquidation value $ 0 $ 0 Due to the availability of historical data from the Company’s recent preferred and common stock sales, Management used a valuation of $ 0.75 1.15 1.15 0.88 The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises. During the years ended December 31, 2017 and 2016, we recognized aggregate stock-compensation expense of $ 2,115,346 1,962,311 0.88 1.25 2,094,360 1,811,990 20,357 145,214 628 5,107
Segment Reporting, Policy [Policy Text Block]	Segment Information The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing a variety of products that support the detection, intervention and monitoring of a range of eye diseases. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company currently accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company determines that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2017 and 2016 and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of December 31, 2017, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense. On December 22, 2017, the President of the United States signed and enacted into law H.R. 1 (the “Tax Reform Law”). The Tax Reform Law, effective for tax years beginning on or after January 1, 2018, except for certain provisions, resulted in significant changes to existing United States tax law, including various provisions that will impact the Company. The Tax Reform Law reduces the federal corporate tax rate from 35 21
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants, options, and shares associated with convertible debt outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares issuable upon exercise of warrants and conversion of convertible debt outstanding are anti-dilutive as they decrease loss per share. December 31, 2017 2016 Warrants 2,983,666 2,923,666 Options 950,000 - Shares issuable upon conversion of convertible preferred stock - 2,841,930 3,933,666 5,765,596
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. Based on the FASB’s Exposure Draft Update issued on April 29, 2015, and approved in July 2015, Revenue from Contracts With Customers (Topic 606): Deferral of the Effective Date, ASU 2014-09 is now effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The Company has not yet evaluated the impact of the adoption of ASU 2016-02 on the Company’s financial statement presentation or disclosures. In March 2016, the FASB issued Accounting Standards Update No. 2016-09 (ASU 2016-09), Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 requires, among other things, that all income tax effects of awards be recognized in the statement of operations when the awards vest or are settled. ASU 2016-09 also allows for an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and allows for a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for any entity in any interim or annual period. The adoption of ASU 2016-09 has not had any impact on the Company’s financial statement presentation or disclosures. Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm to assist management in their determination of the $ 0.88 1.00 Year Ended December 31, 2017 2016 Discount rate 16 % 16 % Risk-free rate 2.48 % 2.27 % Rate of return 16 % 16 % Sustainable growth rate 5 % 5 % Company survival probability 65 % 63 % Liquidation value $ 0 $ 0
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: December 31, 2017 2016 Warrants 2,983,666 2,923,666 Options 950,000 - Shares issuable upon conversion of convertible preferred stock - 2,841,930 3,933,666 5,765,596

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventories consisted of the following: December 31, 2017 2016 Raw materials $ 133,354 $ 40,679 Finished goods 21,376 3,320 $ 154,730 $ 43,999

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment consisted of the following: December 31, 2017 2016 Leasehold improvements $ 98,357 $ 98,357 Testing equipment 150,603 145,503 Furniture and fixtures 50,300 15,348 Computer equipment 16,464 15,277 Office equipment 8,193 2,694 323,917 277,179 Less accumulated depreciation and amortization (228,320) (163,159) $ 95,597 $ 114,020

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2017
Convertible Notes Payable [Member]
Convertible Debt [Table Text Block]	December 31, 2017 2016 Year of issuance: 2010 $ - $ 25,000 Accrued interest - 19,323 Convertible notes payable $ - $ 44,323

Promissory Notes (Tables)

Promissory Notes (Tables)	12 Months Ended
	Dec. 31, 2017
Promissory Notes Payable [Member]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	December 31, 2017 2016 Year of issuance: 2016 $ - $ 10,000 Accrued interest - 251 Promissory notes payable, net $ - $ 10,251

Promissory Notes - Related Pa26

Promissory Notes - Related Party (Tables)	12 Months Ended
	Dec. 31, 2017
Investor [Member]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	December 31, 2017 2016 Year of issuance: 2016 $ - $ 14,000 Accrued interest - 2,805 Promissory notes payable – related party, net $ - $ 16,805

Acquisition of VectorVision (Ta

Acquisition of VectorVision (Tables)	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The following table summarizes the allocation of preliminary fair values of the purchase consideration to the assets and liabilities assumed: Fair Values Common stock consideration $ 2,287,500 Liabilities assumed 108,722 Total purchase consideration 2,396,222 Cash (4,895) Accounts receivable (50,105) Inventory (93,293) Prepaid assets (551) Property and equipment (9,458) Intangible assets (674,400) Goodwill $ 1,563,520
Business Acquisition, Pro Forma Information [Table Text Block]	The following unaudited pro forma financial information gives effect to the Company’s acquisition of VectorVision as if the acquisition had occurred on January 1, 2016 and had been included in the Company’s consolidated statements of operations during the years ended December 31, 2017 and 2016: Year ended 2017 2016 Pro forma net revenues $ 824,028 $ 372,487 Pro forma net loss attributable to common shareholders $ (6,500,590) $ (6,910,705) Pro forma net loss per share $ (0.21) $ (0.28)

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	The approximate future minimum lease payments under non-cancelable operating leases at December 31, 2017 are as follows: Years ending December 31, 2018 $ 93,000 2019 20,898 2020 21,520 2021 22,174 2022 and thereafter 26,670 $ 184,262

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit) (Tables)	12 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Nonvested Restricted Stock Shares Activity [Table Text Block]	Additional details of the Company’s restricted common stock are as follows: Number Fair Value Weighted Average Non-vested, December 31, 2015 1,007,500 $ 833,068 $ 1.14 Issued 145,000 145,438 1.00 Vested (800,000) (864,752) 1.12 Forfeited - - - Non-vested, December 31, 2016 352,500 113,754 1.13 Issued 162,500 143,000 0.88 Vested (515,000) (256,754) 1.05 Forfeited - - - Non-vested, December 31, 2017 - $ - $ -
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the Company’s warrant activity is as follows: Shares December 31, 2015 1,335,166 Granted 1,588,500 Forfeitures - Exercised - December 31, 2016 2,923,666 Granted 60,000 Forfeitures - Exercised - December 31, 2017, all exercisable 2,983,666

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	As of December 31, 2017 and 2016, significant components of the Company’s deferred tax assets were as follows: December 31, 2017 2016 Net operating loss carryforwards $ 1,551,000 $ 3,356,000 Stock-based compensation 504,000 2,016,000 Deferred rent - 9,000 Accrued compensation 17,000 - Depreciation 5,000 1,000 Total deferred tax assets 2,077,000 5,382,000 Valuation allowance (2,077,000) (5,382,000) Net deferred tax assets $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Reconciled below is the difference between the income tax rate computed by applying the U.S. federal statutory rate and the effective tax rates for the years ended December 31, 2017 and 2016: Year Ended December 31, 2017 2016 U. S. federal statutory tax rate (35.0) % (35.0) % Share-based compensation 4.3 % 0.0 % State taxes, net of Federal benefit 0.0 % (6.0) % Adjustment to beginning deferred tax asset 68.5 % 0.0 % Change in valuation allowance (38.0) % 41.0 % Other 0.2 % 0.0 % Effective tax rate 0.0 % 0.0 %

Organization and Business Ope31

Organization and Business Operations (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Net Cash Provided by (Used in) Operating Activities	$ (3,403,696)	$ (1,653,574)
Retained Earnings (Accumulated Deficit), Total	$ (26,865,956)	$ (20,650,207)

Summary of Significant Accoun32

Summary of Significant Accounting Policies (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Discount rate	16.00%	16.00%
Risk-free rate	2.48%	2.27%
Rate of return	16.00%	16.00%
Sustainable growth rate	5.00%	5.00%
Company survival probability	65.00%	63.00%
Liquidation value	$ 0	$ 0

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Details 1) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,933,666	5,765,596
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	950,000	0
Conversion of Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	2,841,930
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,983,666	2,923,666

Summary of Significant Accoun34

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2016
Research and Development Expense		$ 259,463	$ 33,084
Insurance Coverage Limits		$ 250,000
Share Price		$ 1.15	$ 0.88		$ 0.88	$ 1
Allocated Share-based Compensation Expense		$ 2,115,346	$ 1,962,311
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		35.00%	35.00%
Scenario, Plan [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Market Approach Valuation Technique [Member]
Share Price		$ 1.15	$ 0.88	$ 0.75
Third Party [Member]
Share Price		$ 0.88	$ 1
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense		$ 2,094,360	$ 1,811,990
Selling and Marketing Expense [Member]
Allocated Share-based Compensation Expense		20,357	145,214
Research and Development Expense [Member]
Allocated Share-based Compensation Expense		$ 628	5,107
Minimum [Member]
Share Price		$ 0.88
Property, Plant and Equipment, Estimated Useful Lives		three years
Maximum [Member]
Share Price		$ 1.25
Property, Plant and Equipment, Estimated Useful Lives		seven years
Patents [Member]
Research and Development Expense		$ 30,789	$ 30,942

Inventories (Details)

Inventories (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Raw materials	$ 133,354	$ 40,679
Finished goods	21,376	3,320
Inventory, Net, Total	$ 154,730	$ 43,999

Property and Equipment, net (De

Property and Equipment, net (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment, Gross, Total	$ 323,917	$ 277,179
Less accumulated depreciation and amortization	(228,320)	(163,159)
Property, Plant and Equipment, Net, Total	95,597	114,020
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross, Total	98,357	98,357
Testing equipment [Member]
Property, Plant and Equipment, Gross, Total	150,603	145,503
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross, Total	50,300	15,348
Computer Equipment [Member]
Property, Plant and Equipment, Gross, Total	16,464	15,277
Office Equipment [Member]
Property, Plant and Equipment, Gross, Total	$ 8,193	$ 2,694

Property and Equipment, net (37

Property and Equipment, net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Depreciation, Depletion and Amortization, Nonproduction, Total	$ 118,821	$ 60,129
Research and Development Expense	259,463	33,084
General and Administrative Expense, Total	4,683,932	3,339,086
Property, Plant and Equipment [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total	65,161	60,129
Research and Development Expense	29,574	27,490
General and Administrative Expense, Total	$ 35,587	$ 32,639

Convertible Notes Payable (Deta

Convertible Notes Payable (Details) - Convertible Notes Payable [Member] - Unsecured Notes Payable [Member] - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument, Face Amount	$ 0	$ 25,000
Accrued interest	0	19,323
Current portion of notes payable	$ 0	$ 44,323

Convertible Notes Payable (De39

Convertible Notes Payable (Details Textual) - USD ($)	1 Months Ended		12 Months Ended
	May 31, 2015	Jul. 31, 2010	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2017	Sep. 30, 2016
Proceeds from Convertible Debt			$ 0	$ 136,000
Share Price			$ 1.15	$ 0.88	$ 0.88	$ 1
Gain (Loss) on Repurchase of Debt Instrument			$ 0	$ (698,147)
Unsecured Debt [Member]
Proceeds from Convertible Debt				500,000
Interest Payable				$ 41,644
Convertible Notes Payable [Member]
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Proceeds from Convertible Debt	$ 500,000
Convertible Notes Payable [Member] | Unsecured Debt [Member]
Debt Instrument, Interest Rate, Stated Percentage		12.00%
Debt Instrument, Convertible, Conversion Price		$ 0.08
Proceeds from Convertible Debt		$ 25,000
Stock Issued During Period, Shares, Conversion of Convertible Securities				1,408,854
Convertible Notes Payable				$ 19,323
Notes Payable, Fair Value Disclosure				$ 1,239,792

Promissory Notes (Details)

Promissory Notes (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Unsecured Promissory Notes [Member]
Accrued interest		$ 41,644
Notes Payable, Other Payables [Member] | Unsecured Promissory Notes [Member]
Accrued interest	$ 0	251
Promissory notes payable, net	0	10,251
Notes Payable, Other Payables [Member] | 2016 (due June 2016) [Member]
Debt Instrument, Face Amount	$ 0	$ 10,000

Promissory Notes (Details Textu

Promissory Notes (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2017
Proceeds from Notes Payable		$ 100,000	$ 220,000
Short-term Debt				$ 14,000
Stock Issued During Period Shares Conversion of Notes Payable and Related Interest		18,082
Stock Issued During Period Value Conversion of Notes Payable and Related Interest		$ 13,200
2016 Issuances [Member]
Short-term Debt			10,000
Interest Payable, Current		$ 449
2016 Issuances [Member] | Investor [Member]
Proceeds from Notes Payable			140,000
Notes Payable, Other Payables [Member] | 2016 Issuances [Member]
Proceeds from Notes Payable			$ 170,000
Notes Payable, Other Payables [Member] | Minimum [Member] | 2016 Issuances [Member]
Debt Instrument, Interest Rate, Stated Percentage			4.00%
Notes Payable, Other Payables [Member] | Maximum [Member] | 2016 Issuances [Member]
Debt Instrument, Interest Rate, Stated Percentage			9.00%
Promissory Note [Member] | Investor [Member]
Debt Instrument, Convertible, Conversion Price	$ 0.75
Debt Instrument, Face Amount	$ 100,000
Debt Instrument, Term	120 days
Short-term Debt, Percentage Bearing Fixed Interest Rate	6.00%
Debt Conversion, Converted Instrument, Shares Issued	8,000

Promissory Notes - Related Pa42

Promissory Notes - Related Party (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Unsecured Debt [Member]
Accrued interest		$ 41,644
Investor [Member]
Accrued interest	$ 0	2,805
Promissory notes payable - related party, net	0	16,805
2016 (due September 2016) [Member] | Investor [Member] | Unsecured Debt [Member]
Accrued interest	$ 0	$ 14,000

Promissory Notes - Related Pa43

Promissory Notes - Related Party (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2017
Proceeds from Notes Payable	$ 100,000	$ 220,000
Short-term Debt			$ 14,000
2016 Issuances [Member]
Short-term Debt		$ 10,000
Minimum [Member] | Unsecured Debt [Member]
Fair Value Assumptions, Risk Free Interest Rate		6.00%
Maximum [Member] | Unsecured Debt [Member]
Fair Value Assumptions, Risk Free Interest Rate		12.00%
Investor [Member] | 2016 Issuances [Member]
Proceeds from Notes Payable		$ 140,000

Acquisition of VectorVision (De

Acquisition of VectorVision (Details) - USD ($)	1 Months Ended
	Sep. 29, 2017	Dec. 31, 2017	Dec. 31, 2016
Goodwill		$ 1,563,520	$ 0
Vectorvision Inc [Member]
Common stock consideration	$ 2,287,500
Liabilities assumed	108,722
Total purchase consideration	2,396,222
Cash	(4,895)
Accounts receivable	(50,105)
Inventory	(93,293)
Prepaid assets	(551)
Property and equipment	(9,458)
Intangible assets	(674,400)
Goodwill	$ 1,563,520

Acquisition of VectorVision (45

Acquisition of VectorVision (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Pro forma net revenues	$ 824,028	$ 372,487
Pro forma net loss attributable to common shareholders	$ (6,500,590)	$ (6,910,705)
Pro forma net loss per share	$ (0.21)	$ (0.28)

Acquisition of VectorVision (46

Acquisition of VectorVision (Details Textual)	1 Months Ended
	Sep. 29, 2017USD ($)$ / sharesshares
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares	3,050,000
Equity Method Investment, Ownership Percentage	11.00%
Vectorvision Inc [Member]
Business Acquisition, Equity Interest Issued or Issuable, Description	With respect to the 3,050,000 shares of common stock, 250,000 shares were held back as security for VectorVisions indemnification obligations to the Company and the remaining 2,800,000 shares were issued to VectorVision at the closing of the transaction.
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable | $	$ 2,287,500
Business Acquisition, Share Price | $ / shares	$ 0.75

Commitments and Contingencies47

Commitments and Contingencies (Details)	Dec. 31, 2017USD ($)
2,018	$ 93,000
2,019	20,898
2,020	21,520
2,021	22,174
2022 and thereafter	26,670
Operating Leases, Future Minimum Payments Due, Total	$ 184,262

Commitments and Contingencies48

Commitments and Contingencies (Details Textual)	12 Months Ended
	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Sep. 29, 2017USD ($)a	Oct. 31, 2012ft²
Average Monthly Lease Payments	$ 10,387		$ 1,799
Deposit Paid for Lease	47,449
Deposit Paid for Prepaid Rent	36,979
Deposit On Lease Agreement	10,470
Operating Leases, Rent Expense	111,167	$ 106,217
Area of Land			5,000	9,605
Loss Contingency, Damages Sought, Value	192,000
Accrued Rent	$ 1,650	$ 88,290

Stockholders_ Equity (Deficit49

Stockholders’ Equity (Deficit) (Details) - Restricted Stock [Member] - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Number of Shares, Beginning Balance	352,500	1,007,500
Number of Shares, Issued	162,500	145,000
Number of Shares, Vested	(515,000)	(800,000)
Number of Shares, Forfeited	0	0
Number of Shares, Ending Balance	0	352,500
Fair Value, Beginning Balance	$ 113,754	$ 833,068
Fair Value, Issued	143,000	145,438
Fair Value, Vested	(256,754)	(864,752)
Fair Value, Forfeited	0	0
Fair Value, Ending Balance	$ 0	$ 113,754
Weighted Average Grant Date Fair Value Per Share, Beginning Balance	$ 1.13	$ 1.14
Weighted Average Grant Date Fair Value Per Share, Issued	0.88	1
Weighted Average Grant Date Fair Value Per Share, Vested	1.05	1.12
Weighted Average Grant Date Fair Value Per Share, Forfeited	0	0
Weighted Average Grant Date Fair Value Per Share, Ending Balance	$ 0	$ 1.13

Stockholders_ Equity (Deficit50

Stockholders’ Equity (Deficit) (Details 1) - shares	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Class of Warrant or Right [Line Items]
Membership Units or Shares, Balance	2,923,666	1,335,166
Membership Units or Shares, Granted	60,000	1,588,500
Membership Units or Shares, Forfeitures	0	0
Membership Units or Shares, Exercised	0	0
Membership Units or Shares, Balance	2,983,666	2,923,666

Stockholders_ Equity (Deficit51

Stockholders’ Equity (Deficit) (Details Textual) - USD ($)	Nov. 10, 2017	Dec. 30, 2017	Nov. 03, 2017	Jun. 30, 2016	May 31, 2016	Dec. 31, 2016	Sep. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Jun. 30, 2017	Jan. 31, 2017	Sep. 30, 2016
Class of Warrant or Right [Line Items]
Common Stock, Par or Stated Value Per Share						$ 0.001		$ 0.001	$ 0.001
Share-based Compensation								$ 1,932,268	$ 787,684
Stock Issued During Period, Shares, Issued for Services			205,242
Class of Warrant or Right, Outstanding						2,923,666		2,983,666	2,923,666	1,335,166
Warrants Weighted Average Remaining Life								10 months 24 days
Warrants Intrinsic Value								$ 1,293,512
Share Price						$ 0.88		$ 1.15	$ 0.88		$ 0.88		$ 1
Stock Issued During Period, Value, New Issues								$ 5,000,001
Convertible Preferred Stock, Terms of Conversion									The Series A Preferred Stock (including accrued but unpaid dividends) shall automatically convert into shares of common stock in the event that the Company receives gross proceeds of at least $4,000,000 in one or more equity financing transactions subsequent to September 30, 2016, or if the ten (10) day Volume Weighted Average Price per share of common stock is $2.00 or more.
Accretion of Dividends						$ 760,011		$ 414,293	$ 760,011			$ 19,575
Debt Conversion, Original Debt, Amount									$ 535,149
Common Stock Dividends, Shares								191,227
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate								2.48%	2.27%
Interest Expense, Total								$ 23,727	$ 1,104,557
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate								16.00%	16.00%
Stock Issued								$ 308,628	$ 35,018
Gain (Loss) on Repurchase of Debt Instrument								0	(698,147)
Stock Issued During Period, Value, Conversion of Convertible Securities								$ 0
Deemed Dividend						$ 779,586			$ 779,586
Convertible Preferred Stock, Shares Issued upon Conversion			6,981,938
Preferred Stock, Shares Issued						1,705,154		0	1,705,154
Non Qualified Stock Options [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation								$ 878,818
Share Price							$ 0.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares							650,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate							1.63%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate							123.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							1,250,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price							$ 1
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award							5 years
Stock Granted, Value, Share-based Compensation, Gross							$ 934,804
Warrant [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.75	$ 0.37
Warrants To Purchase Common Stock Shares							60,000
Consultant [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period								690,755		1,053,227
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period								1,053,227
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease)								362,472
Consultant [Member] | Non Qualified Stock Options [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation		$ 434,959
Share Price		$ 1.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		250,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		2.01%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		123.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		750,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 1.25
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award		5 years
Stock Granted, Value, Share-based Compensation, Gross		$ 936,834
Employee [Member] | Non Qualified Stock Options [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation	$ 143,750
Share Price	$ 1.15
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.01%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	123.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	125,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 1.15
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award	10 years
Stock Granted, Value, Share-based Compensation, Gross	$ 143,750
Restricted Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, Issued for Services								1,007,500
Stock Issued During Period, Value, Issued for Services								$ 833,680
Share Price						$ 1		$ 0.88	$ 1
Stock Issued During Period, Shares, New Issues									145,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period								162,500	145,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value								$ 256,754	$ 864,752
Restricted Stock or Unit Expense									864,752	$ 864,752
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value								143,000	145,438
Stock Issued During Period, Value, Conversion of Convertible Securities									$ 113,754
Dividend Declared [Member]
Class of Warrant or Right [Line Items]
Dividends, Preferred Stock, Stock								114,736
Post-Maturity Warrants [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation				$ 98,505	$ 246,341
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				100,000	250,000
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.25	$ 0.25	0.25			$ 0.25
Share Price				$ 1	$ 1	$ 1			$ 1
Debt Instrument, Interest Rate, Stated Percentage						12.00%			12.00%
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period									585,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value				$ 98,505	$ 246,341				$ 575,673
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate									118.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				1.07%	1.08%				1.01%
Interest Expense, Total									$ 575,673
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				116.00%	116.00%
Common Stock [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation								$ 401,037	$ 560,932
Stock Issued During Period, Shares, Issued for Services								486,800	595,000
Stock Issued During Period, Shares, New Issues								4,347,827
Stock Issued During Period, Value, New Issues								$ 4,348
Debt Conversion, Original Debt, Amount									$ 687,368
Convertible Common Stock, Conversion Price						$ 602,741			$ 602,741
Accrued Professional Fees						$ 410,960			$ 410,960
Debt Conversion, Converted Instrument, Shares Issued									1,651,732
Stock Issued									$ 1,385,516
Stock Issued During Period, Value, Conversion of Convertible Securities								$ 6,982
Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Debt Conversion, Converted Instrument, Shares Issued									535,154
Stock Issued									$ 784,888
Private Placement [Member]
Class of Warrant or Right [Line Items]
Common Stock, Par or Stated Value Per Share			$ 0.001
Stock Issued During Period, Shares, Issued for Services			4,347,827
Shares Issued, Price Per Share			$ 1.15
Proceeds from Issuance of Private Placement			$ 5,000,001
Other Issuance [Member] | Common Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues									684,933
Stock Issued During Period, Value, New Issues									$ 191,781
Series A Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Shares Issued, Price Per Share						$ 1			$ 1
Share Price						$ 1			$ 1
Stock Issued During Period, Shares, New Issues								0
Stock Issued During Period, Value, New Issues								$ 0
Preferred Stock, Dividend Rate, Percentage									8.00%
Preferred Stock, Dividends Per Share, Declared									$ 0.60
Preferred Stock, Value, Outstanding								250,000
Stock Issued During Period, Value, Conversion of Convertible Securities								$ (1,705)
Preferred Stock, Shares Issued							300,000
Series A Preferred Stock [Member] | Private Placement [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Value, New Issues						$ 500,000
Series A Preferred Stock [Member] | Other Issuance [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues									1,170,000
Stock Issued During Period, Value, New Issues									$ 1,170,000
Series B Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Debt Conversion, Converted Instrument, Warrants or Options Issued								60,000
Share Price							$ 1
Stock Issued During Period, Shares, New Issues								0
Stock Issued During Period, Value, New Issues								$ 0
Preferred Stock, Dividend Rate, Percentage							6.00%
Preferred Stock, Dividends Per Share, Declared							$ 0.75
Convertible Preferred Stock, Terms of Conversion							The stock is automatically convertible by the Company upon an equity financing of at least $5,000,000 subsequent to June 30, 2017, or in the event the Companys common stock is publicly traded for at least $2.00 per share for 10 consecutive trading days, or upon completion of a Major Transaction (as defined in the Certificate of Designation).
Common Stock Dividends, Shares								261,135
Stock Issued During Period, Value, Conversion of Convertible Securities								$ (3,105)
Deemed Dividend							$ 582,377
Series B Preferred Stock [Member] | Dividend Declared [Member]
Class of Warrant or Right [Line Items]
Dividends, Preferred Stock, Stock								$ 193,892
Series B Preferred Stock [Member] | Other Issuance [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues							3,105,000
Stock Issued During Period, Value, New Issues							$ 3,105,000

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	1 Months Ended		12 Months Ended
	Nov. 03, 2017	Sep. 29, 2017	Dec. 31, 2017	Dec. 31, 2016
Related Party Transaction [Line Items]
Due to Related Parties, Current			$ 146,133	$ 91,483
Stock Issued During Period, Value, New Issues			5,000,001
Share-based Compensation			$ 1,932,268	787,684
Stock Issued During Period, Shares, Issued for Services	205,242
Equity Method Investment, Ownership Percentage		11.00%
Related Party Transaction, Terms and Manner of Settlement		3
Related Party Transaction, Description of Transaction		entitled to compensation of $10,000 per month for the first six months of the term of the Consulting Agreement and $7,500 per month for the remainder of the term of the Consulting Agreement.
Vectorvision Inc [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Issued for Services		3,050,000
Common Stock [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues			4,347,827
Stock Issued During Period, Value, New Issues			$ 4,348
Share-based Compensation			$ 401,037	$ 560,932
Stock Issued During Period, Shares, Issued for Services			486,800	595,000
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Payments to Employees			$ 170,000	$ 48,500
Debt Conversion, Converted Instrument, Amount				$ 410,960
Stock Issued During Period, Shares, Issued for Services				50,000
Chief Executive Officer [Member] | Common Stock [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues				684,933
Stock Issued During Period, Value, New Issues				$ 602,741
Vice President [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Issued for Services				20,000
General Counsel and Corporate Secretary [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Issued for Services				15,000
Controller [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, Issued for Services				5,000
David W. Evans [Member] | Vectorvision Inc [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage		28.00%
Tamara Evans [Member] | Vectorvision Inc [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage		72.00%
General and Administrative Expense [Member]
Related Party Transaction [Line Items]
Share-based Compensation				$ 191,781
General and Administrative Expense [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Officers' Compensation			$ 250,000	250,000
Stock Based Compensation Award [Member]
Related Party Transaction [Line Items]
Share-based Compensation				$ 162,800

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Line Items]
Net operating loss carryforwards	$ 1,551,000	$ 3,356,000
Stock-based compensation	504,000	2,016,000
Deferred rent	0	9,000
Accrued compensation	17,000	0
Depreciation	5,000	1,000
Total deferred tax assets	2,077,000	5,382,000
Valuation allowance	(2,077,000)	(5,382,000)
Net deferred tax assets	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Line Items]
U. S. federal statutory tax rate	(35.00%)	(35.00%)
Share-based compensation	4.30%	0.00%
State taxes, net of Federal benefit	0.00%	(6.00%)
Adjustment to beginning deferred tax asset	68.50%	0.00%
Change in valuation allowance	(38.00%)	41.00%
Other	0.20%	0.00%
Effective tax rate	0.00%	0.00%

Income Taxes (Details Textual)

Income Taxes (Details Textual)	12 Months Ended
	Dec. 31, 2017USD ($)
Income Taxes [Line Items]
Operating Loss Carryforwards	$ 5,566,000
Operating Loss Carryforwards Expiration Year	2,035

Subsequent Events (Details Text

Subsequent Events (Details Textual) - Subsequent Event [Member] - Consultant [Member]	1 Months Ended
	Jan. 26, 2018$ / sharesshares
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	500,000
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award	5 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares	$ 1.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	250,000
December 31, 2018 [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	125,000
December 31, 2019 [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	125,000